MacroGenics, Inc. (MGNX:NASDAQ) closed at $2.34 on November 9, 2026, up 0.43% on the day. The stock trades 53.9% below its 52-week high of $5.08 and 77.3% above its 52-week low of $1.32. Over the past year, it gained 70.1%. MacroGenics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 7, 2025, MGNX closed higher on 124 days (49%). Its best day was March 10, 2026 (+45.34%) and its worst was October 23, 2026 (-38.02%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 3 times.
MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-d...
Find more stocks like MGNX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.